GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (STU:ANWA) » Definitions » Research & Development

Immuron (STU:ANWA) Research & Development : €2.29 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Immuron Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Immuron's Research & Development for the six months ended in Dec. 2023 was €1.63 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was €2.29 Mil.

Immuron Research & Development Historical Data

The historical data trend for Immuron's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Research & Development Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Research & Development
Get a 7-Day Free Trial Premium Member Only 0.64 0.72 0.87 0.44 1.61

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.19 0.97 0.66 1.63

Immuron Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immuron  (STU:ANWA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Immuron Research & Development Related Terms

Thank you for viewing the detailed overview of Immuron's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuron (STU:ANWA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (STU:ANWA) » Definitions » Research & Development
Comparable Companies
ASX:NOX ASX:ACR ASX:CHM ASX:1AI ASX:ATX ASX:ATH ASX:PAB ASX:RAD ASX:BTC ASX:1AD OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
IMRN:USA ANWA:Germany IMC:Australia
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Website
https://www.immuron.com.au
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (STU:ANWA) Headlines

No Headlines